THE ROLE OF HEXAMIDINE DIISETHIONATE (ZAMIDINE®) 1MG/ML 0.6ML EYE DROPS IN THE PROPHYLAXIS OF SURGERY OFTALMIC

Last updated: January 8, 2025
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergy

Eye Disease

Eye Disorders/infections

Treatment

Conjunctival Swab

Clinical Study ID

NCT06771908
7172
  • Ages 18-90
  • All Genders

Study Summary

Data will be gathered from patients who report having any kind of recurrent conjunctivitis and who, in accordance with clinical practice, are scheduled to have intravitreal injections, glaucoma surgery, cataract surgery, vitrectomy, combined cataract and vitrectomy, or corneal transplantation.

The data will be obtained using pseudonyms from the patients' medical records and will include the outcomes of swabs and surgeries performed in accordance with clinical practice for the patient's condition.

The following swabs will be taken into consideration for data analysis:

Four days before to surgery, a conjunctival swab is used to check for the presence and load of species that do not make up the typical conjunctival flora (Baseline-T0).

On the day of operation, a conjunctival swab is taken before to entering the recovery room (T1).

Following three minutes of 5% iodopovidone instillation in the eye to be operated on, a conjunctival swab (T2) was used.

Additionally, we will gather follow-up data from the medical record 24 and 30 hours after surgery (at day 34 +/- 7 days).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18 years or older, male and female;

  2. Patient requiring ophthalmic surgery (intravitreal injections, glaucoma surgery,cataract surgery, vitrectomy, combined cataract and vitrectomy, cornealtransplantation) and in need of antiseptic surgical prophylaxis (e.g., Zamidine®)

  3. Positive history of recurrent conjunctivitis in the eye requiring surgery.

  4. Written informed consent.

Exclusion

Exclusion Criteria:

  1. Age < 18 years;

  2. Refusal to give informed consent.

Study Design

Total Participants: 56
Treatment Group(s): 1
Primary Treatment: Conjunctival Swab
Phase:
Study Start date:
February 01, 2025
Estimated Completion Date:
February 01, 2026

Study Description

To determine if Zamidine® reduces ocular surface bacterial flora in surgical prophylaxis.

Secondary goals. To quantify and qualitatively evaluate ocular surface bacterial flora,

  • Compare bacterial load before and after surgery with 5% iodopovidone.

  • Determine sample endophthalmitis incidence. The study will include patients who are scheduled for intravitreal injections, glaucoma surgery, cataract surgery, vitrectomy, combined cataract and vitrectomy, corneal transplantation, and any type of recurrent conjunctivitis.

Data from patients' medical records will be pseudonymized and contain swabs and operation findings according to clinical practice for their condition.

Following swabs will be analyzed for data:

  • a conjunctival swab four days before surgery to detect and quantify non-native organisms.

A conjunctival swab before operation day's recovery room (T1).

  • a conjunctival swab (T2) after 3 minutes of 5% iodopovidone in the operative eye.

Follow-up data at 24 and 30 days after surgery (day 34 +- 7 days) will be collected from the medical record.

Connect with a study center

  • Prof. Stanislao Rizzo

    Rome, 00168
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.